Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

In vivo recruitment of hematopoietic cells using stromal cell-derived factor 1 alpha-loaded heparinized three-dimensional collagen scaffolds.

Bladergroen BA, Siebum B, Siebers-Vermeulen KG, Van Kuppevelt TH, Poot AA, Feijen J, Figdor CG, Torensma R.

Tissue Eng Part A. 2009 Jul;15(7):1591-9. doi: 10.1089/ten.tea.2008.0348.

PMID:
19108679
2.

Monocyte cell surface glycosaminoglycans positively modulate IL-4-induced differentiation toward dendritic cells.

den Dekker E, Grefte S, Huijs T, ten Dam GB, Versteeg EM, van den Berk LC, Bladergroen BA, van Kuppevelt TH, Figdor CG, Torensma R.

J Immunol. 2008 Mar 15;180(6):3680-8.

3.

Human mast cells produce and release the cytotoxic lymphocyte associated protease granzyme B upon activation.

Strik MC, de Koning PJ, Kleijmeer MJ, Bladergroen BA, Wolbink AM, Griffith JM, Wouters D, Fukuoka Y, Schwartz LB, Hack CE, van Ham SM, Kummer JA.

Mol Immunol. 2007 Jul;44(14):3462-72. Epub 2007 May 7.

PMID:
17485116
4.

Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.

van Houdt IS, Oudejans JJ, van den Eertwegh AJ, Baars A, Vos W, Bladergroen BA, Rimoldi D, Muris JJ, Hooijberg E, Gundy CM, Meijer CJ, Kummer JA.

Clin Cancer Res. 2005 Sep 1;11(17):6400-7.

5.

The granzyme B inhibitor proteinase inhibitor 9 (PI9) is expressed by human mast cells.

Bladergroen BA, Strik MC, Wolbink AM, Wouters D, Broekhuizen R, Kummer JA, Hack CE.

Eur J Immunol. 2005 Apr;35(4):1175-83.

6.

Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas.

Muris JJ, Meijer CJ, Cillessen SA, Vos W, Kummer JA, Bladergroen BA, Bogman MJ, MacKenzie MA, Jiwa NM, Siegenbeek van Heukelom LH, Ossenkoppele GJ, Oudejans JJ.

Leukemia. 2004 Mar;18(3):589-96.

PMID:
14712286
7.

Production, characterization, and use of serpin antibodies.

Kummer JA, Strik MC, Bladergroen BA, Hack CE.

Methods. 2004 Feb;32(2):141-9. Review.

PMID:
14698626
8.

Intracellular serpin SERPINB6 (PI6) is abundantly expressed by human mast cells and forms complexes with beta-tryptase monomers.

Strik MC, Wolbink A, Wouters D, Bladergroen BA, Verlaan AR, van Houdt IS, Hijlkema S, Hack CE, Kummer JA.

Blood. 2004 Apr 1;103(7):2710-7. Epub 2003 Dec 11.

9.

Distribution of the human intracellular serpin protease inhibitor 8 in human tissues.

Strik MC, Bladergroen BA, Wouters D, Kisiel W, Hooijberg JH, Verlaan AR, Hordijk PL, Schneider P, Hack CE, Kummer JA.

J Histochem Cytochem. 2002 Nov;50(11):1443-54.

PMID:
12417609
10.

Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma.

ten Berge RL, Meijer CJ, Dukers DF, Kummer JA, Bladergroen BA, Vos W, Hack CE, Ossenkoppele GJ, Oudejans JJ.

Blood. 2002 Jun 15;99(12):4540-6.

11.

Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?

Bladergroen BA, Meijer CJ, ten Berge RL, Hack CE, Muris JJ, Dukers DF, Chott A, Kazama Y, Oudejans JJ, van Berkum O, Kummer JA.

Blood. 2002 Jan 1;99(1):232-7.

12.

Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells.

Medema JP, Schuurhuis DH, Rea D, van Tongeren J, de Jong J, Bres SA, Laban S, Toes RE, Toebes M, Schumacher TN, Bladergroen BA, Ossendorp F, Kummer JA, Melief CJ, Offringa R.

J Exp Med. 2001 Sep 3;194(5):657-67.

13.

The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites.

Bladergroen BA, Strik MC, Bovenschen N, van Berkum O, Scheffer GL, Meijer CJ, Hack CE, Kummer JA.

J Immunol. 2001 Mar 1;166(5):3218-25.

14.

Cloning and expression of CTP:phosphoethanolamine cytidylyltransferase cDNA from rat liver.

Bladergroen BA, Houweling M, Geelen MJ, van Golde LM.

Biochem J. 1999 Oct 1;343 Pt 1:107-14.

15.

Inhibition of phosphatidylcholine and phosphatidylethanolamine biosynthesis in rat-2 fibroblasts by cell-permeable ceramides.

Bladergroen BA, Bussière M, Klein W, Geelen MJ, Van Golde LM, Houweling M.

Eur J Biochem. 1999 Aug;264(1):152-60.

16.
17.

Channelling of intermediates in the biosynthesis of phosphatidylcholine and phosphatidylethanolamine in mammalian cells.

Bladergroen BA, Geelen MJ, Reddy AC, Declercq PE, Van Golde LM.

Biochem J. 1998 Sep 15;334 ( Pt 3):511-7.

18.

Reversible translocation of CTP:phosphocholine cytidylyltransferase from cytosol to membranes in the adult bovine liver around parturition.

Bladergroen BA, Wensing T, Van Golde LM, Geelen MJ.

Biochim Biophys Acta. 1998 Mar 30;1391(2):233-40.

PMID:
9555031
19.

CTP:phosphoethanolamine cytidylyltransferase.

Bladergroen BA, van Golde LM.

Biochim Biophys Acta. 1997 Sep 4;1348(1-2):91-9. Review.

PMID:
9370320
20.

Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues.

Van der Ven LT, Roholl PJ, Gloudemans T, Van Buul-Offers SC, Welters MJ, Bladergroen BA, Faber JA, Sussenbach JS, Den Otter W.

Br J Cancer. 1997;75(11):1631-40.

21.

Growth advantage of human leiomyoma cells compared to normal smooth-muscle cells due to enhanced sensitivity toward insulin-like growth factor I.

van der Ven LT, Gloudemans T, Roholl PJ, van Buul-Offers SC, Bladergroen BA, Welters MJ, Sussenbach JS, den Otter W.

Int J Cancer. 1994 Nov 1;59(3):427-34.

PMID:
7927953
22.

Identification of novel phosphorylation sites in the beta-subunit of translation initiation factor eIF-2.

Welsh GI, Price NT, Bladergroen BA, Bloomberg G, Proud CG.

Biochem Biophys Res Commun. 1994 Jun 30;201(3):1279-88.

PMID:
8024572

Supplemental Content

Loading ...
Support Center